Vaccines

This becomes the first state in the United States to do so, and of course, this decision will affect the childhood vaccine schedule in Florida. Infectious Diseases Society of America (IDSA) President, Tina Tan, MD, weighs in on this decision and what this could mean for an increase of vaccine-preventable diseases and who would be vulnerable to them.

CDC survey found increased vaccination coverage among adolescents in 2024, with the exception of HPV, as childhood vaccinations decline.

Results from a Danish trial of more than 330,000 adults 65 years or older found high- and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.

Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.

New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.

From chikungunya setbacks to COVID-19 booster guidance and childhood vaccine safety initiatives, here are the top regulatory and research developments this summer.

Allergist and immunologist Juanita Mora, MD, urges vaccination, masking, and outreach to safeguard vulnerable communities.

The American College of Cardiology is providing recommendations on the influenza, COVID-19, RSV vaccinations and others.

Regulators cite four new serious adverse event reports, halting US distribution while global access efforts continue.

New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.

The renewed federal panel aims to improve vaccine oversight and restore public trust amid declining immunization rates and ongoing concerns about vaccine ingredients.

As virus season begins, Leilani Valdes, MD, MBA, FCAP, highlights the lab’s role in early detection and the importance of informed, respectful dialogue on vaccines.

After a three-month review, the FDA and EMA have cleared continued use of IXCHIQ in adults 60+, adding new safety warnings for elderly individuals with chronic conditions.

Low vaccine uptake, immunity gaps, and new antiviral data raise alarms ahead of a potential late-summer surge.

Study reveals notable sex-based disparities in liver complication risk among adults with cirrhosis, particularly in nonviral cases.

In a continuing trend from the last several years, a record number of families are opting out of vaccines.

Vinay Prasad’s, MD, MPH, short tenure marked by tough regulatory decisions and political pushback; the Trump administration has not yet named a successor for the CBER director role.

This comes after the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) made the recommendation to remove the vaccine preservative.

First author Jacek Skarbinski, MD, offers insights on new data published last week showing how this population can benefit from continued vaccination.

A large study looked at booster uptake and effectiveness among US adults who received chemotherapy or immunotherapy.

New format eliminates reconstitution step, offering greater convenience for providers and supporting expanded access for at-risk adults.

New research finds no link between aluminum in vaccines and autism, asthma, or other health conditions, strengthening the case for vaccine safety.

The company said it expects to have its updated mRNA-1273 (Spikevax) vaccine available for these eligible populations in the US for the next respiratory virus season.

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.